Authors
Latest:
The Virtual Window: Clinical Trial Reports--March 2007Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.
Latest:
Oncology Practices Face the Biggest Change in Coding Since the Computer-ICD-10Set for full rollout on October 1, the much delayed 10th revision of the International Statistical Classification of Diseases and Related Health Problems is probably the biggest revision to medical coding and billing since computerized medical coding and billing practices began decades ago.
Latest:
Results of a Combined Modality Screening Approach in Women Without Cancer HistoryNickolas Papadopoulos, PhD, professor of oncology and pathology, Johns Hopkins University School of Medicine, discusses the results of a study which evaluated a combined modality screening approach in women without a history of cancer.
Latest:
Dr. Normanno on Using Circulating Tumor DNA for EGFR DetectionNicola Normanno, MD, chief of the Cell Biology and Biotherapy Unit, INT-Fondazione Pascale, Naples, Italy, discusses the benefit of plasma genotyping to predict response to EGFR-targeted therapy in patients with non-small cell lung cancer (NSCLC).
Latest:
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLCNicolas Girard, MD, discusses both de novo and acquired resistance alterations in HER2-altered non–small cell lung cancer.
Latest:
Oncology Practice Vitality Depends on LeadershipThe pace of consolidation shows no sign of slowing down, and this trend also applies to oncology, as more and more community-based oncology practices are joining large health systems.
Latest:
Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MDDrs Danilov and Lamanna discuss key efficacy data from the final comparative analysis of the ALPINE trial of zanubrutinib in relapsed/refractory CLL.
Latest:
Long-Term Experience With Ibrutinib in CLLJennifer Woyach, MD, discusses her experience using ibrutinib for chronic lymphocytic leukemia (CLL) in the first-line setting.
Latest:
Dr. Reinmuth on the Rationale for Examining PROs With Tepotinib in METex14-Altered NSCLCNiels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.
Latest:
Dr. Mettu on the Potential of CPI-613 in Metastatic Pancreatic CancerNiharika B. Mettu, MD, PhD, assistant professor medicine, Duke Cancer Institute, discusses the potential of CPI-613 in the treatment of patients with metastatic pancreatic cancer.
Latest:
Dr Munshi on the Background of the CARTITUDE-1 Trial in Multiple MyelomaNikhil C. Munshi, MD, discusses the background of the phase 1b/2 CARTITUDE-1 trial of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and highlights the specific patient population enrolled in the study.
Latest:
Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced MelanomaNikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.
Latest:
Dr. Ghosh on the Safety Data Seen With Liso-cel in LBCLNilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.
Latest:
The Role of Radiation in the Management of Brain MetastasesIn this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.
Latest:
Dr. Nimmi Kapoor on Multigene Panel Testing for Hereditary Breast CancerNimmi Kapoor, MD, Breast and Thyroid Surgical Oncologist at Breastlink, discusses the benefits and safety of multigene panel testing in patients at risk for hereditary breast cancer.
Latest:
Unmet Needs in the Management of Multiple MyelomaSagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.
Latest:
Dr. Peled on the Rationale of Evaluating Lenvatinib/Pembrolizumab with Chemotherapy in NSCLCNir Peled, MD, PhD, FCCP, discusses the rationale of evaluating the combination of lenvatinib and pembrolizumab plus chemotherapy in non–small cell lung cancer.
Latest:
Dr. Mehta Discusses the Reliability of Automated Segmentation for Lung Volumes in Multiple CancersNiraj Mehta, MD, Radiation Oncologist, 21st Century Oncology, discusses the reliability of automated segmentation for lung volumes in breast, lung, and esophageal cancers.
Latest:
Dr. Shah on CAR T-Cell Therapy in Pediatric ALLNirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.
Latest:
Dr Shah on Unmet Needs in the Treatment of Older Patients with DLBCLNirav N. Shah, MD, discusses the rationale for launching a phase 2 trial of split-dose R-CHOP in older patients with diffuse large B-cell lymphoma, touching on the unmet needs seen in the treatment of this population.
Latest:
Oncology Fellow Stresses Integrity in the Lab and ClinicResearch forms the backbone of medical knowledge, and research integrity is a crucial responsibility of any scientist.
Latest:
Dr. Bansal on Chemotherapeutic Approaches for Patients With Ovarian CancerNisha Bansal, MD, gynecologic oncologist, University of California, Los Angeles, discusses frontline chemotherapeutic approaches for patients with ovarian cancer.
Latest:
Dr. Thawani on AEs With Radiation Versus COVID-19 Symptoms in Lung CancerNitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.
Latest:
Multidisciplinary Approach to Managing Treatment for Relapsed/Refractory CLLPanelists discuss how their institutions organize multidisciplinary teams for chronic lymphocytic leukemia care, detailing the specific roles of various specialists including oncologists, nurses, pharmacists, and cardiologists in coordinating comprehensive patient care, managing adverse events, and addressing treatment-related complications throughout the course of therapy.
